Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis

Exclusion Criteria

• •1. Patients with hemodynamic instability;
• •2. Patients with obvious liver and kidney function injury: bilirubin,aminotransferase (ALT, AST) exceeded the upper limit of normal by 2 times; eGFR \< 60ml/min or dialysis patients;
• •3. Patients allergic to upadacitinib or its excipients;
• •4. Patients whose primary disease was gastrointestinal malignancy;
• •5. Patients currently suffering from serious or uncontrolled underlying diseases of the blood, digestive tract, metabolism, endocrine, lung, heart, nervous system, mental system, etc.;
• •6. Female patients during pregnancy and breastfeeding (including patients with reproductive needs)；
• •7. Patients with current infection with infectious diseases (hepatitis B, hepatitis C, syphilis, AIDS, tuberculosis, etc.);
• •8. Patients with missing key data for outcome assessment;
• •9. Any other circumstances which, in the opinion of the investigator, would render the subject unfit for study inclusion.